Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 22, 2011 - Issue 6
Submit an article Journal homepage
407
Views
14
CrossRef citations to date
0
Altmetric
Biologics

Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: A meta-analysis

Ji Ying Tan Evidence-based Medicine Center;Institute of ImmunologyCorrespondence[email protected]
,
Shaohong Li Evidence-based Medicine Center;Institute of Immunology
,
Kehu Yang Evidence-based Medicine Center
,
Bin Ma Evidence-based Medicine Center
,
Wanqiang ChenInstitute of Clinical Medicine of Integrated Western and Chinese Medicine
,
Chengxi ZhaInstitute of Biochemistry and Molecular Biology, School of Basic Medical Science, Lanzhou University, Lanzhou, GanSu, China
&
Junying ZhangInstitute of Clinical Medicine of Integrated Western and Chinese Medicine
 show all
Pages 323-336 | Received 23 Mar 2010, Accepted 28 Mar 2010, Published online: 05 Oct 2010

References

  • Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–1912.
  • Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14(3):485–496.
  • Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Etanercept and efalizumab for the treatment of psoriasis: A systematic review. Health Technol Assess. 2006;10(46):1–233.
  • Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: A review. Australas J Dermatol. 2004;45(3):155–159.
  • Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–284.
  • Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392.
  • Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236–244.
  • De Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140–147.
  • Du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111(5):581–583.
  • Van Weelden H, Baart de la Faille H, Young E, van der Leun JC. Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol. 1990;70(3):212–215.
  • Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med. 1997;336(15):1041–1045.
  • Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol. 1997;137(6):943–949.
  • Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol. 2004;195(3):298–308.
  • Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: Traditional therapy. Ann Rheum Dis. 2005;(64 suppl 2):ii83–ii86.
  • Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke WH, Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol. 2004;50(5):734–739.
  • Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–640.
  • Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
  • Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
  • Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–592.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.